Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Fluorescence In Situ Hybridization Analysis Of Circulating Tumor Cells In Metastatic Prostate Cancer
M. Leversha, J. Han, Z. Asgari, D. Danila, O. Lin, Rita Gonzalez-Espinoza, A. Anand, H. Lilja, G. Heller, M. Fleisher, H. Scher
Published 2009 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Purpose: To assess the feasibility of characterizing gene copy number alteration by fluorescence in situ hybridization (FISH) of circulating tumor cells (CTC) isolated using the CellSearch system in patients with progressive castration-resistant metastatic prostate cancer. Experimental Design: We used probe combinations that included the androgen receptor (AR) and MYC genes for FISH analysis of CTC samples collected from 77 men with castration-resistant metastatic prostate cancer. Results: High-level chromosomal amplification of AR was detected in 38% and relative gain of MYC in 56% of samples analyzed. No such abnormalities were detected in samples with CTC counts of <10, reflecting ascertainment difficulty in these lower count samples. Conclusion: The CTC isolated from our patient cohort present a very similar molecular cytogenetic profile to that reported for late-stage tumors and show that FISH analysis of CTC can be a valuable, noninvasive surrogate for routine tumor profiling. That as many as 50% of these patients have substantial amplification of the AR locus indicates that androgen signaling continues to play an important role in late-stage prostate cancer.
This paper references
Fluorescence in situ hybridization.
C. M. Price (1993)
Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.
T. Fehm (2002)
Distribution of Human Chromosome Counts in Relation to Age
P. A. Jacobs (1961)
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.
K. Sato (1999)
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma Imaging
R B Jenkins
Circulating tumor cells predict overall survival following treatment in metastatic prostate cancer
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
T. Visakorpi (1995)
Amplification of the androgen receptor gene in bone metastases from hormone‐refractory prostate cancer
R. S. Brown (2002)
Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone‐refractory recurrent prostate cancer
P. Koivisto (1997)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
J. D. de Bono (2008)
Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer
D. Shaffer (2007)
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
R. Jenkins (1997)
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.
H. Scher (2004)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
M. Cristofanilli (2004)
Cytogenetic analysis of Circulating Tumor Cells of metastatic prostate cancer
A. Tibbe (2008)
Phase I/II study ofMDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC)
HI Scher (2008)
Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics
H. Engel (1999)
Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer.
N. Tsuchiya (2002)
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping.
M. Cher (1996)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
G. Attard (2008)
DNA microarrays for comparative genomic hybridization based on DOP‐PCR amplification of BAC and PAC clones
H. Fiegler (2003)
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
P. Koivisto (1997)
Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases
W. Allard (2004)
Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.
L. Bubendorf (1999)
Prognostic value of deoxyribonucleic acid content in prostate cancer: A review of current results
J. Adolfsson (1994)
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
D. Danila (2007)
The new cytogenetics: blurring the boundaries with molecular biology
M. Speicher (2005)
Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC)
H. Scher (2008)
Androgen receptor amplification is associated with increased cell proliferation in prostate cancer.
K. Haapala (2007)
Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas
F. R. Ribeiro (2006)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
H. Scher (2008)
FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, AR) in prostatic carcinomas before and after androgen deprivation therapy
C Kaltz-Wittmer (2000)
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
S. Cohen (2008)
Genetic Evaluation of Localized Prostate Cancer in a Cohort of Forty Patients: Gain Of Distal 8q Discriminates Between Progressors and Nonprogressors
H. Dekken (2003)
FISH Analysis of Gene Aberrations (MYC, CCND1, ERBB2, RB, and AR) in Advanced Prostatic Carcinomas Before and After Androgen Deprivation Therapy
C. Kaltz-Wittmer (2000)
This paper is referenced by
Circulating Tumor Cells as an Analytical Tool in the Management of Patients with Cancer
D. Danila (2016)
The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis
L. Xu (2017)
Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance
Yun-fan Sun (2011)
Mechanisms of resistance to intermittent androgen deprivation in prostate cancer patients identified by a novel computational method
Jason D. Morken (2014)
Current and emerging treatments in the management of castration-resistant prostate cancer
David Shapiro (2012)
Circulating tumour cells—monitoring treatment response in prostate cancer
D. Miyamoto (2014)
Enrichment of prostate cancer cells from blood cells with a hybrid dielectrophoresis and immunocapture microfluidic system
C. Huang (2013)
[Circulating tumor cells and advanced prostate cancer].
T. Murez (2012)
A new toolbox for assessing single cells.
Konstantinos Tsioris (2014)
Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis.
M. Magbanua (2013)
Notes for developing a molecular test for the full characterization of circulating tumor cells.
E. Rossi (2015)
Gene Technology: Applications and Techniques
P. Bisen (2012)
Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
T. Kobayashi (2013)
Amplification and protein expression of androgen receptor gene in prostate cancer cells: Fluorescence in situ hybridization analysis.
X. Zhang (2015)
The challenge of gene expression profiling in heterogeneous clinical samples.
F. Rodríguez-González (2013)
Dormancy in solid tumors: implications for prostate cancer
N. Ruppender (2013)
The application of circulating tumor cells detecting methods in veterinary oncology.
M. Chmielewska (2013)
Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castrationresistant prostate cancer: a report from the PETRUS prospective study
C. Massard (2016)
Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer
M. Kohli (2012)
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
C. P. Carden (2010)
Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer
S. Denmeade (2010)
Targeting the PI 3 K / Akt / mTOR pathway in castration-resistant prostate cancer
R. Bitting (2013)
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer
R. Hu (2010)
Circulating Tumors Cells as Biomarkers: Progress Toward Biomarker Qualification
D. Danila (2011)
Molecular analysis of circulating tumour cells—biology and biomarkers
M. Krebs (2014)
Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer
T. Naito (2012)
Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell capture
C. Huang (2013)
Androgen receptor (AR) aberrations in castration-resistant prostate cancer
K. Waltering (2012)
When Prostate Cancer Circulates in the Bloodstream
V. Vlaeminck-Guillem (2015)
Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer
M. Gorin (2017)
Affinity Versus Label-Free Isolation of Circulating Tumor Cells: Who Wins?
Vasudha Murlidhar (2016)
Hormone-Based Therapies for Castration-Resistant Prostate Cancer
E. Mostaghel (2013)See more